As of the latest Form 4 filed Jun 22, 2026.
What Tarsus Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 36 most recent filings for TARS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-22 | 2026-06-17 | Azamian Bobak R. President/CEO and Board Chair | SSale | −5.42K | $61.81 | $335K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Azamian Bobak R., President/CEO and Board Chair | SSale | −4.58K | $61.24 | $281K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Farrow Jeffrey S See Remarks | SSale | −14.4K | $60.95 | $877K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Goodrich Katherine Director | SSale | −2.95K | $62.08 | $183K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Farrow Jeffrey S See Remarks | MExercise | +27.9K | — | — | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | LINK WILLIAM J PHD Director | SSale | −1.93K | $62.94 | $121K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | LINK WILLIAM J PHD, Director | SSale | −10.6K | $61.97 | $655K | Yes (planned) | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | Goodrich Katherine Director | MExercise | +2.95K | — | — | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | Goldberg Andrew D. Director | MExercise | +2.95K | — | — | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | Morrison Scott W Director | MExercise | +2.95K | — | — | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | CHAUDHURI BHASKAR Director | MExercise | +2.95K | — | — | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | LINK WILLIAM J PHD Director | MExercise | +2.95K | — | — | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | YARNO WENDY L Director | MExercise | +2.95K | — | — | No | Form 4 ↗ |
| 2026-04-28 | 2026-04-24 | PYOTT DAVID E I Director | MExercise | +1.38K | — | — | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Neervannan Seshadri Chief Operating Officer | SSale | −2.99K | $66.75 | $200K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-19 | Lin Elizabeth Yeu Chief Medical Officer | SSale | −390.00 | $67.00 | $26.1K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-19 | Wahl Bryan General Counsel | SSale | −4.23K | $67.00 | $283K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-19 | Whitfield Dianne C. Chief Human Resources Officer | SSale | −4.17K | $67.00 | $280K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-19 | Azamian Bobak R. President/CEO and Board Chair | SSale | −12.0K | $67.00 | $802K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-19 | Neervannan Seshadri Chief Operating Officer | SSale | −4.59K | $67.00 | $307K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-19 | Mottiwala Aziz Chief Commercial Officer | SSale | −4.44K | $67.00 | $297K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-19 | Farrow Jeffrey S See Remarks | SSale | −2.19K | $67.00 | $146K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Lin Elizabeth Yeu Chief Medical Officer | SSale | −379.00 | $68.71 | $26.0K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Wahl Bryan General Counsel | SSale | −4.13K | $68.71 | $283K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Whitfield Dianne C. Chief Human Resources Officer | SSale | −4.07K | $68.71 | $280K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Azamian Bobak R. President/CEO and Board Chair | SSale | −11.7K | $68.71 | $802K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Neervannan Seshadri Chief Operating Officer | SSale | −3.61K | $68.71 | $248K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Mottiwala Aziz Chief Commercial Officer | SSale | −4.33K | $68.71 | $298K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Farrow Jeffrey S See Remarks | SSale | −2.13K | $68.71 | $147K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Lin Elizabeth Yeu Chief Medical Officer | SSale | −375.00 | $69.42 | $26.0K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Wahl Bryan General Counsel | SSale | −4.08K | $69.42 | $284K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Whitfield Dianne C. Chief Human Resources Officer | SSale | −4.03K | $69.42 | $280K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Azamian Bobak R. President/CEO and Board Chair | SSale | −11.0K | $69.42 | $762K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Neervannan Seshadri Chief Operating Officer | SSale | −3.13K | $69.42 | $217K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Mottiwala Aziz Chief Commercial Officer | SSale | −4.29K | $69.42 | $298K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Farrow Jeffrey S See Remarks | SSale | −2.11K | $69.42 | $147K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also TARS’s full analysis or the market-wide insider trading feed. The tabs above jump to TARS’s other SEC data.
Source: SEC Form 4 filings for TARS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.